Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 5;21(1):18.
doi: 10.1186/s12933-022-01454-3.

The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury

Affiliations

The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury

Florian Kahles et al. Cardiovasc Diabetol. .

Abstract

Background: The gut incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide) are secreted by enteroendocrine cells following food intake leading to insulin secretion and glucose lowering. Beyond its metabolic function GIP has been found to exhibit direct cardio- and atheroprotective effects in mice and to be associated with cardiovascular prognosis in patients with myocardial infarction. The aim of this study was to characterize endogenous GIP levels in patients with acute myocardial infarction.

Methods and results: Serum concentrations of GIP were assessed in 731 patients who presented with clinical indication of coronary angiography. Circulating GIP levels were significantly lower in patients with STEMI (ST-elevation myocardial infarction; n=100) compared to clinically stable patients without myocardial infarction (n=631) (216.82 pg/mL [Q1-Q3: 52.37-443.07] vs. 271.54 pg/mL [Q1-Q3: 70.12-542.41], p = 0.0266). To characterize endogenous GIP levels in patients with acute myocardial injury we enrolled 18 patients scheduled for cardiac surgery with cardiopulmonary bypass and requirement of extracorporeal circulation as a reproducible condition of myocardial injury. Blood samples were drawn directly before surgery (baseline), upon arrival at the intensive care unit (ICU), 6 h post arrival to the ICU and at the morning of the first and second postoperative days. Mean circulating GIP concentrations decreased in response to surgery from 45.3 ± 22.6 pg/mL at baseline to a minimum of 31.9 ± 19.8 pg/mL at the first postoperative day (p = 0.0384) and rose again at the second postoperative day (52.1 ± 28.0 pg/mL).

Conclusions: Circulating GIP levels are downregulated in patients with myocardial infarction and following cardiac surgery. These results might suggest nutrition-independent regulation of GIP secretion following myocardial injury in humans.

Keywords: Cardiac injury; Cardiac surgery; GIP; Incretin; Myocardial infarction.

PubMed Disclaimer

Conflict of interest statement

The authors do not have any competing interest.

Figures

Fig. 1
Fig. 1
Serum GIP levels are downregulated in patients with acute myocardial infarction (Clinical study I): Circulating serum GIP levels from patients with acute myocardial infarction (STEMI; n = 100) compared to clinically stable patients without myocardial infarction (n = 631). A Wilcoxon rank-sum test was performed (p = 0.0266)
Fig. 2
Fig. 2
Serum GIP levels are decreased in response to cardiac surgery (Clinical study II): Kinetics of serum GIP levels over time after cardiac surgery (time point 1: at baseline before cardiac surgery, time point 2: at arrival to the ICU (4–6 h post initiation of surgery), time point 3: 6 h post arrival to the ICU (10–12 h post initiation of surgery), time points 4 and 5: in the morning one and two days after surgery). A linear mixed model for logarithmized GIP values with time point as independent factor, a random patient effect and a compound symmetry covariance structure was computed (time point effect p = 0.0105). P-values for the comparison between time points 2– to 1 (baseline) were adjusted using the Dunnett-Hsu adjustment for multiple comparisons (comparison between time point 4 and baseline p = 0.0384)

References

    1. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525–536. doi: 10.1016/S2213-8587(15)00482-9. - DOI - PubMed
    1. Asmar M, Asmar A, Simonsen L, Gasbjerg LS, Sparre-Ulrich AH, Rosenkilde MM, Hartmann B, Dela F, Holst JJ, Bulow J. The gluco- and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor. Diabetes. 2017;66(9):2363–2371. doi: 10.2337/db17-0480. - DOI - PubMed
    1. Lehrke M, Marx N. New antidiabetic therapies: innovative strategies for an old problem. Current opinion in lipidology. 2012;23(6):569–575. doi: 10.1097/MOL.0b013e328359b19f. - DOI - PubMed
    1. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15–30. doi: 10.1016/j.cmet.2016.06.009. - DOI - PubMed
    1. Burgmaier M, Liberman A, Mollmann J, Kahles F, Reith S, Lebherz C, Marx N, Lehrke M. Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe(-)/(-) mice. Atherosclerosis. 2013;231(2):427–435. doi: 10.1016/j.atherosclerosis.2013.08.033. - DOI - PubMed

Publication types

MeSH terms